Hypercholesterolemia
Conditions
Keywords
hypercholesterolemia, NCEP ATP III guidelines, survey
Brief summary
The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 2 or more risk factors (according to NCEP ATP III guideline) * Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.
Exclusion criteria
* Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site). * Previous enrolment or randomisation of treatment in the present study. * Participation in a clinical study during the last 90 days.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number and percentage of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP Ⅲ guidelines(overall and by country) | After collecting all Patient Record Form. |
Secondary
| Measure | Time frame |
|---|---|
| The number and percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP Ⅲ guidelines for several subject subsets. | After collecting all Patient Record Form. |
| The association between achievement of LDL-C goals,according to the updated 2004 NCEP ATPⅢ guidelines and patient and physician variables. | After collecting all Patient Record Form. |
| The physician characteristics associated with the allocation of hypercholesterolemia treatment regime. | After collecting all Patient Record Form. |
Countries
China, Indonesia, Malaysia, Philippines, South Korea, Taiwan, Thailand, Vietnam
Outcome results
None listed